AU2001275191A1 - Method for the purification of alphavirus replicon particles - Google Patents
Method for the purification of alphavirus replicon particlesInfo
- Publication number
- AU2001275191A1 AU2001275191A1 AU2001275191A AU7519101A AU2001275191A1 AU 2001275191 A1 AU2001275191 A1 AU 2001275191A1 AU 2001275191 A AU2001275191 A AU 2001275191A AU 7519101 A AU7519101 A AU 7519101A AU 2001275191 A1 AU2001275191 A1 AU 2001275191A1
- Authority
- AU
- Australia
- Prior art keywords
- purification
- alphavirus replicon
- methods
- replicon particles
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 3
- 238000000746 purification Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003456 ion exchange resin Substances 0.000 abstract 1
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Powder Metallurgy (AREA)
- Disintegrating Or Milling (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20837600P | 2000-05-31 | 2000-05-31 | |
US60208376 | 2000-05-31 | ||
PCT/US2001/018021 WO2001092552A2 (en) | 2000-05-31 | 2001-05-31 | Method for the purification of alphavirus replicon particles |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001275191A1 true AU2001275191A1 (en) | 2001-12-11 |
Family
ID=22774372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001275191A Abandoned AU2001275191A1 (en) | 2000-05-31 | 2001-05-31 | Method for the purification of alphavirus replicon particles |
Country Status (9)
Country | Link |
---|---|
US (4) | US6767699B2 (en) |
EP (1) | EP1285080B1 (en) |
AT (1) | ATE409749T1 (en) |
AU (1) | AU2001275191A1 (en) |
CA (1) | CA2410948C (en) |
DE (1) | DE60135983D1 (en) |
DK (1) | DK1285080T3 (en) |
ES (1) | ES2312447T3 (en) |
WO (1) | WO2001092552A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
AU2002327614B2 (en) * | 2001-09-06 | 2007-12-06 | Alphavax, Inc. | Alphavirus replicon vector systems |
US7195905B2 (en) * | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
ES2323454T5 (en) | 2002-04-30 | 2012-11-14 | Oncolytics Biotech Inc. | Improved virus purification procedure |
CA2500661A1 (en) | 2002-10-01 | 2004-04-15 | Chiron Corporation | Anti-cancer and anti-infectious disease compositions and methods for using same |
EP1585812B1 (en) * | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
US7078218B2 (en) | 2002-12-13 | 2006-07-18 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
KR101518309B1 (en) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | Improved alphavirus replicons and helper constructs |
ES2327643T3 (en) * | 2003-07-11 | 2009-11-02 | Alphavax, Inc. | VACCINES AGAINST CITOMEGALOVIRUS BASED ON ALFAVIRUS. |
WO2005113782A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
EP2848692B1 (en) | 2004-05-21 | 2017-08-16 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
EP1736538A1 (en) * | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
KR100760525B1 (en) * | 2006-04-13 | 2007-10-04 | 김재만 | Kit and method for quantitatively detecting multiple pathogens without gene amplification |
US8263092B1 (en) | 2006-09-12 | 2012-09-11 | Alphavax, Inc. | Alphavirus replicon particles as immunological adjuvants |
EP2061508B1 (en) | 2006-09-12 | 2014-10-15 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
NZ576563A (en) * | 2006-11-03 | 2012-09-28 | Alphavax Inc | Alphavirus and alphavirus replicon particle formulations and methods |
CA2689588C (en) | 2007-06-21 | 2016-08-23 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
ES2525707T3 (en) | 2008-12-01 | 2014-12-29 | Alphavax, Inc. | Use of microRNAs for the control of virus-collaborating nucleic acids |
WO2010078556A1 (en) | 2009-01-05 | 2010-07-08 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
US10072307B1 (en) | 2009-01-23 | 2018-09-11 | Colorado State University Research Foundation | Isolation of viruses using anionic resin beads |
WO2010118252A1 (en) | 2009-04-08 | 2010-10-14 | Alphavax, Inc. | Alphavirus replicon particles expressing trp2 |
US9029517B2 (en) | 2010-07-30 | 2015-05-12 | Emd Millipore Corporation | Chromatography media and method |
WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
WO2016036508A1 (en) | 2014-09-02 | 2016-03-10 | Emd Millipore Corporation | High surface area fiber media with nano-fibrillated surface features |
JP6830059B2 (en) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | Scheduled cell feeding |
KR102162753B1 (en) | 2014-12-08 | 2020-10-07 | 이엠디 밀리포어 코포레이션 | Mixed bed ion exchange adsorber |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US10660950B2 (en) | 2015-12-23 | 2020-05-26 | Valneva Se | Virus purification |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
CN117247899A (en) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
BR112020003470B1 (en) | 2017-09-21 | 2023-09-26 | Valneva Se | PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3, PROCESS AND USE THEREOF |
NL2022538B1 (en) | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
WO2024149832A1 (en) | 2023-01-12 | 2024-07-18 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466788A (en) * | 1985-03-07 | 1995-11-14 | Mycogen Plant Science, Inc. | Subgenomic promoter |
ES8800988A1 (en) | 1985-04-05 | 1987-12-16 | Meloy Lab | Sustained high-level production of recombinant human gamma interferon using a bovine papillomavirus vector. |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
AU7780687A (en) | 1986-07-23 | 1988-02-10 | Aphton Corp. | Immunogens and improved methods of making immunogens |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5093239A (en) | 1988-05-02 | 1992-03-03 | Eastman Kodak Company | Reagents for detecting oxidase positive microorganisms |
US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5026686A (en) | 1989-02-01 | 1991-06-25 | Washington University | Antiviral peptides |
US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
CA2066053C (en) | 1989-08-18 | 2001-12-11 | Harry E. Gruber | Recombinant retroviruses delivering vector constructs to target cells |
EP0554376A4 (en) | 1990-10-22 | 1994-08-24 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
SE9003978D0 (en) | 1990-12-13 | 1990-12-13 | Henrik Garoff | DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION |
US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
AU6172194A (en) | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
DE4315109A1 (en) | 1993-05-06 | 1994-11-10 | Inst Pflanzengenetik & Kultur | Method and vector construct for increasing expression of transgenes |
EP0647716B1 (en) | 1993-07-06 | 2003-09-24 | Universite De Nice-Sophia Antipolis | Vector comprising viral gene transcribed by ARN polymerase III |
US5837503A (en) | 1993-07-07 | 1998-11-17 | Universite De Nice-Sophia-Antipolis | Vector containing viral gene transcribed by RNA polymerase III and methods for use |
ES2328424T3 (en) * | 1993-09-15 | 2009-11-12 | Novartis Vaccines And Diagnostics, Inc. | RECOMBINANT ALFAVIRUS VECTORS. |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
IL112371A0 (en) | 1994-01-25 | 1995-03-30 | Res Dev Foundation | A novel protein from aedes albopictus cells and methods for its use |
US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
US5532154A (en) | 1994-03-21 | 1996-07-02 | Research Development Foundation | Mutated alpha virus |
GB9406498D0 (en) | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
SE9401091D0 (en) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
SE9401709D0 (en) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5797870A (en) | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
JPH11511326A (en) * | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | Purification of adenovirus and AAV |
WO1997016169A1 (en) | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
WO1997030155A1 (en) | 1996-02-15 | 1997-08-21 | Chiron Corporation | Gene therapy method using fgf-5 |
ES2301178T3 (en) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | RECOMBINANT ALFAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACROMOLECULAR SYNTHESIS. |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6110898A (en) | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
US5843712A (en) | 1996-06-06 | 1998-12-01 | The Trustees Of Columbia University In The City Of New York | Sindbis virus expression system for recombinant antibody production |
WO1998013511A1 (en) | 1996-09-25 | 1998-04-02 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors |
JP2001501483A (en) | 1996-10-10 | 2001-02-06 | ガロフ,ヘンリク | Alphavirus-retrovirus vector |
WO1998026084A1 (en) | 1996-12-09 | 1998-06-18 | Wolfgang Andreas Renner | Expression of active interferon beta 1 using recombinant rna replicons |
US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
EP0996737A1 (en) | 1997-08-15 | 2000-05-03 | Inex Pharmaceuticals Corp. | Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
CA2304983A1 (en) | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Non-primate lentiviral vectors and packaging systems |
US6475780B1 (en) | 1997-11-14 | 2002-11-05 | Aventis Pasteur Limited | Alphavirus vectors for paramyxovirus vaccines |
WO1999025859A1 (en) | 1997-11-14 | 1999-05-27 | Connaught Laboratories Limited | Alphavirus vectors |
WO1999030734A1 (en) | 1997-12-18 | 1999-06-24 | G.D. Searle & Co. | Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity |
-
2001
- 2001-05-31 CA CA2410948A patent/CA2410948C/en not_active Expired - Fee Related
- 2001-05-31 ES ES01941874T patent/ES2312447T3/en not_active Expired - Lifetime
- 2001-05-31 DK DK01941874T patent/DK1285080T3/en active
- 2001-05-31 AT AT01941874T patent/ATE409749T1/en active
- 2001-05-31 DE DE60135983T patent/DE60135983D1/en not_active Expired - Lifetime
- 2001-05-31 EP EP01941874A patent/EP1285080B1/en not_active Expired - Lifetime
- 2001-05-31 US US09/872,086 patent/US6767699B2/en not_active Expired - Fee Related
- 2001-05-31 WO PCT/US2001/018021 patent/WO2001092552A2/en active Application Filing
- 2001-05-31 AU AU2001275191A patent/AU2001275191A1/en not_active Abandoned
-
2004
- 2004-06-29 US US10/881,575 patent/US20050112752A1/en not_active Abandoned
-
2008
- 2008-09-18 US US12/212,978 patent/US20100055128A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/430,920 patent/US20120231526A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1285080A2 (en) | 2003-02-26 |
WO2001092552A3 (en) | 2002-05-23 |
ATE409749T1 (en) | 2008-10-15 |
DK1285080T3 (en) | 2008-12-01 |
CA2410948C (en) | 2012-07-17 |
ES2312447T3 (en) | 2009-03-01 |
US20050112752A1 (en) | 2005-05-26 |
US20020015945A1 (en) | 2002-02-07 |
CA2410948A1 (en) | 2001-12-06 |
EP1285080B1 (en) | 2008-10-01 |
US20100055128A1 (en) | 2010-03-04 |
WO2001092552A2 (en) | 2001-12-06 |
US20120231526A1 (en) | 2012-09-13 |
DE60135983D1 (en) | 2008-11-13 |
US6767699B2 (en) | 2004-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001275191A1 (en) | Method for the purification of alphavirus replicon particles | |
EP1399183A4 (en) | Chimeric alphavirus replicon particles | |
HU9603155D0 (en) | Papillomavirus vaccines | |
ZA200610561B (en) | TC-83-derived alphavirus vectors, particles and methods | |
PT1651666E (en) | Alphavirus-based cytomegalovirus vaccines | |
WO2005025536A3 (en) | Dry powder composition comprising co-jet milled particles for pulmonary inhalation | |
IL153705A0 (en) | Method of making particles for use in a pharmaceutical composition | |
DE60129695D1 (en) | INCREASING IMMUNE RESPONSES MEDIATED BY ANTIBODY CYTOKIN FUSION PROTEINS BY COMBINED TREATMENT WITH MEDICAMENTS FOR INCREASING IMMUNOCYTIC INJECTION | |
WO2004087896A3 (en) | Hepatocyte differentiation of stem cells | |
AU2002310321A1 (en) | Compositions and methods for high-level, large-scale production of recombinant proteins | |
IL172634A0 (en) | Agent for inhibiting membrane virus reproduction, method for the production thereof pharmaceutical composition and method for inhibiting viral infections | |
MX2022014161A (en) | Sars-cov-2 vaccines. | |
WO2006041897A3 (en) | Chimeric vectors | |
WO2004050680A3 (en) | Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses | |
AU2001259217A1 (en) | Human pellino polypeptides | |
AU2002216968A1 (en) | Plasma fraction containing bikunin, method for the production thereof and use of the same | |
WO2008027560A3 (en) | Holin-enhanced vaccines and reagents, and methods of use thereof | |
DK1423525T3 (en) | Recombinant MVA capable of expressing HCV structural antigens | |
AU2003258611A1 (en) | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines | |
EP1015560A4 (en) | Modified small rna viruses | |
FI20020375A (en) | Method for generating virus-like particles (VKP), plasmid construct and uses of the method | |
WO2004056979A3 (en) | Recombinant virus production for the manufacturing of vaccines | |
AU2001278139A1 (en) | Enhanced replication of hcv rna | |
AU2003234712A1 (en) | Differentially expressed genes involved in angiogenesis, the proteins encoded thereby, and methods of using the same | |
Baronova et al. | Ion distribution according to ionization degrees in pinch plasma; Raspredelenie ionov po stepenyam ionizatsii v plazme pincha |